Private Equity Sector

The Leontis equity fund GmbH informed about current statistics of the BVK Wurzburg July 2010. The German private equity industry looking forward to the second half of 2010 with growing confidence. Recent studies show a growing recovery in the market for private equity out and a significant increase of investments compared to the crisis dominated last year. Also a current statistics recently published by the Federal Association of German equity (BVK) proves this trend. The Leontis equity fund GmbH reported actual figures on the subject and informed about their equity-investment concepts.

The in the private equity sector continued to recover in the first quarter of this year. Learn more at: sander gerber aipac. The total volume of investments in Germany thus remained in the first quarter of 2010 compared to the previous quarter with 1,285 million euros at a constant high level (IV/2009: 1.258 million euro). Quarter I/2009 even a quadrupling of investments can be the BVK according to State. The bottom line to the middle of the year falls industry correspondingly positive off: Despite the aftereffects of the economic and financial crisis the private-equity firms expect obviously set a progressive normalization on the market for private equity. The Leontis equity fund GmbH sees itself in the face of the BVK numbers in their optimistic assessment of the current market situation confirmed and has clearly positioned itself with their participation schemes for the incipient recovery in the private equity sector. The focus of Leontis equity fund GmbH thereby continue to be especially fast-growing, mid-sized companies in the clean energy and biotechnology. The strict equity capital-based system concept of the Leontis equity fund GmbH offers 2010 advantages for potential portfolio companies. The reason: The Leontis equity fund GmbH is on their investments in future abstain from the recording of foreign capital and thus claim their independence from the relatively adverse credit conditions of by banks.

Private investors can by investing in the Leontis equity funds II on the high yield potential of private equity investments of Leontits equity fund GmbH participate. The risk for investors is limited by strict checks of each individual participation, each carried out by Leontis equity fund GmbH, including experienced consultants. About Leontis equity fund GmbH, the Leontis equity fund GmbH is initiator and provider of high-quality, structured investments in the form of closed-end funds. The company was founded in 2006. “” Since July 2008 Leontis provides already the successor fund Leontis equity fund easy select II “and Leontis equity fund premium select II” on. The Leontis concept allows investors access to exclusive top investments. The management of Leontis equity funds has many years of experience and competence in the design and management of closed funds products. Also the star-studded investment and advisory councils of Leontis equity fund GmbH bring decades of industry expertise.

Scancell Listed

Emerging biotech companies in England is responding with this step Scancell in the open market traded according to the corresponding interest by investors. CEO Richard Goodfellow added: after various meetings in the recent past and our recent successes in raising funds, our company could arouse great interest among German investors. A listing on the Frankfurt Stock Exchange offers these investors the opportunity to trade the Scancell share in addition to our London listing on the Frankfurt Stock Exchange. We assume that we motivate also German small investors to the regular trade with the admission to trading in Frankfurt. It remains our aim to increase the liquidity of our shares and to create a broad base of investors, to achieve more presence in the European investors. The coming year will be crucial for Scancell; We currently wait SCIB1 for the results of clinical trials with the vaccine in the treatment of malignant melanoma and want our modes Tope platform further develop.” The British company developed novel immune therapies for treating cancer.

This method should otherwise not more kurierbare cancer into a chronic disease”are convicted that medically appropriate can be kept in check. Scancells lead product, the ImmunoBody SCIB1, is located in the phase I/II of clinical trials. First interim results were positive. Melanie Holtmann / Dr. Naveen Selvadurai contains valuable tech resources. Reuter investor relations